Send to

Choose Destination
Clin Infect Dis. 2006 Apr 1;42(7):e61-5. Epub 2006 Feb 21.

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases.

Author information

University of Minnesota, Minneapolis, Minnesota, USA.

Erratum in

  • Clin Infect Dis. 2006 Nov 15;43(10):1376.


To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis (proven zygomycosis, 69 patients; probable zygomycosis, 22 patients). Patients had infection that was refractory to prior antifungal treatment (n=81) or were intolerant of such treatment (n=10) and participated in the compassionate-use posaconazole (800 mg/day) program. The rate of success (i.e., either complete or partial response) at 12 weeks after treatment initiation was 60%, and 21% of patients had stable disease. The overall high success and survival rates reported here provide encouraging data regarding posaconazole as an alternative therapy for zygomycosis.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center